Progressive multifocal leukoencephalopathy and multiple sclerosis: Lessons from natalizumab
Three patients have developed progressive multifocal leukoencephalopathy while being treated with natalizumab for their autoimmune diseases. One patient had relapsing-remitting multiple sclerosis (RRMS), one had Crohn’s disease, and one (who had been enrolled in an RRMS phase III trial) had no evidence of multiple sclerosis on autopsy. The patient with RRMS now has severe, permanent neurologic damage and the other two patients died. In this article, we recommend revised entry and diagnostic criteria to prevent enrollment of RRMS patients with a favorable prognosis or questionable diagnosis into trials of drugs with unknown safety profiles. In light of the risk of progressive multifocal leukoencephalopathy, we strongly recommend that RRMS patients who are at low risk of disability not be treated with natalizumab. Finally, we discuss what additional natalizumab efficacy data need to be presented before any decisions should be made about treating RRMS patients with a high risk of developing long-term disability.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.Kleinschmidt-DeMasters BK, Tyler KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005, 353:369–374. The case report of the woman in Colorado without any evidence of MS on autopsy.PubMedCrossRefGoogle Scholar
- 2.Langer-Gould A, Atlas SW, Bollen AW, Pelletier D: Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005, 353:375–381. The case report of the man with RRMS in California who developed an aggressive inflammatory reaction to PML 3 months after cessation of natalizumab.PubMedCrossRefGoogle Scholar
- 3.Van Assche G, Van Ranst M, Sciot R, et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 2005, 353:362–368. The case report of the Belgian man with a complicated treatment history for Crohn’s disease who died of PML while on natalizumab monotherapy.PubMedCrossRefGoogle Scholar
- 10.Major E, Ryschkewitsch D, Fahle G, et al.: The laboratory evaluation for JC Virus DNA in cerebrospinal fluid and plasma from multiple sclerosis patients participating in the phase III clinical trials of natalizumab [abstract]. Multiple Sclerosis 2005, 11(Suppl 1):679.Google Scholar
- 15.Black WC, Welch HG: Screening for disease. Am J Roentgenol 1997, 168:3–11.Google Scholar
- 17.Langer-Gould A, Popat R, Huang S, et al.: Clinical and demographic predictors of long term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. N Engl J Med 2006, In press.Google Scholar
- 25.Kruit MC, van Buchem MA, Hofman PA, et al.: Migraine as a risk factor for subclinical brain lesions. JAMA 2004, 291:427–434. A population-based cross-sectional study that characterizes the type of imaging abnormalities found in higher frequency in migraine patients as compared with age- and sex-matched control subjects. It also identifies clinical and demographic features of migraine patients at highest risk of subclinical brain lesions.PubMedCrossRefGoogle Scholar
- 26.Nilsson P, Larsson EM, Maly-Sundgren P, et al.: Predicting the outcome of optic neuritis evaluation of risk factors after 30 years of follow-up. J Neurol 2005, 252:396–402. This is a retrospective cohort study of optic neuritis patients that describes their brain imaging characteristics, clinical diagnoses, and prognosis after 30 years. It shows that many of the optic neuritis patients who never suffered any recurrent symptoms meet current MS MRI diagnostic criteria, thus calling into question the prognostic significance of these criteria.PubMedCrossRefGoogle Scholar
- 29.Polman CH, O’Connor PW, Havrdova-Eat AI: Clinical results from AFFIRM: a randomized, placebo-controlled, multicenter trial to determine the efficacy and safety of natalizumab in patients with relapsing multiple sclerosis. American Academy of Neurology, Miami Beach, Florida 2005, 64:A146. Abstract S116.003.Google Scholar
- 30.Rudick R, Stuart W, Calabrese Pat SI: SENTINEL: a randomized, double-blind, placebo-controlled, multicenter trial to determine the efficacy and safety of natalizumab, when added to intramuscular interferon beta-1a, in patients with relapsing multiple sclerosis. One-year clinical and MRI results. American Academy of Neurology, Miami Beach, Florida 2005, 64: A276. Abstract S236.001.Google Scholar